BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bonnetain F, Paoletti X, Collette S, Doffoel M, Bouché O, Raoul JL, Rougier P, Masskouri F, Barbare JC, Bedenne L. Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials. Qual Life Res 2008;17:831-43. [PMID: 18618292 DOI: 10.1007/s11136-008-9365-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Sawamoto R, Nagano J, Kajiwara E, Sonoda J, Hiramoto T, Sudo N. Inhibition of emotional needs and emotional wellbeing predict disease progression of chronic hepatitis C patients: an 8-year prospective study. Biopsychosoc Med 2016;10:24. [PMID: 27478498 DOI: 10.1186/s13030-016-0075-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Soto J, Rejas J, Ruiz M, Pardo A. Estudios de calidad de vida relacionada con la salud incluidos en ensayos clínicos: valoración de su calidad metodológica mediante de una lista-guía. Medicina Clínica 2009;133:314-20. [DOI: 10.1016/j.medcli.2009.04.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
3 Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes 2009;7:102. [PMID: 20030832 DOI: 10.1186/1477-7525-7-102] [Cited by in Crossref: 309] [Cited by in F6Publishing: 293] [Article Influence: 23.8] [Reference Citation Analysis]
4 Li L, Chan SL, Mo F, Hui EP, Koh J, Chan AK, Tang NL, Chu CM, Hui J, Lee KF, Yu S, Yeo W. Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients. Qual Life Res 2019;28:2597-607. [PMID: 31037590 DOI: 10.1007/s11136-019-02190-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
5 Osoba D. Health-related quality of life and cancer clinical trials. Ther Adv Med Oncol 2011;3:57-71. [PMID: 21789156 DOI: 10.1177/1758834010395342] [Cited by in Crossref: 107] [Cited by in F6Publishing: 101] [Article Influence: 9.7] [Reference Citation Analysis]
6 Firkins JL, Tarter R, Driessnack M, Hansen L. A closer look at quality of life in the hepatocellular carcinoma literature. Qual Life Res 2021;30:1525-35. [PMID: 33625648 DOI: 10.1007/s11136-021-02789-2] [Reference Citation Analysis]
7 Marino P, Bannier M, Moulin J, Gravis G. Rôle et utilisation des Patient reported outcomes (PROs) dans la prise en charge des patients en oncologie. Bulletin du Cancer 2018;105:603-9. [DOI: 10.1016/j.bulcan.2018.02.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
8 Gmür A, Kolly P, Knöpfli M, Dufour J. FACT-Hep increases the accuracy of survival prediction in HCC patients when added to ECOG Performance Status. Liver Int 2018;38:1468-74. [DOI: 10.1111/liv.13711] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
9 Zhou K, Fountzilas C. Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E861. [PMID: 31234316 DOI: 10.3390/cancers11060861] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
10 Li L, Mo FK, Chan SL, Hui EP, Tang NS, Koh J, Leung LK, Poon AN, Hui J, Chu CM. Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data. BMC Cancer. 2017;17:8. [PMID: 28052758 DOI: 10.1186/s12885-016-2995-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
11 Li TC, Li CI, Tseng CH, Lin KS, Yang SY, Chen CY, Hsia TC, Lee YD, Lin CC. Quality of life predicts survival in patients with non-small cell lung cancer. BMC Public Health 2012;12:790. [PMID: 22978682 DOI: 10.1186/1471-2458-12-790] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
12 Velanovich V, Wollner I. Quality of life and performance status in patients with pancreatic and periampullary tumors. Int J Clin Oncol 2011;16:401-7. [PMID: 21347628 DOI: 10.1007/s10147-011-0200-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
13 Chiu CC, Lee KT, Wang JJ, Sun DP, Lee HH, Shi HY. Health-Related Quality of Life before and after Surgical Resection of Hepatocellular Carcinoma: A Prospective Study. Asian Pac J Cancer Prev 2018;19:65-72. [PMID: 29373894 DOI: 10.22034/APJCP.2018.19.1.65] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
14 Xing M, Kokabi N, Camacho JC, Kim HS. Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization. BMC Cancer 2018;18:75. [PMID: 29329568 DOI: 10.1186/s12885-017-3921-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
15 Li D, Sedano S, Allen R, Gong J, Cho M, Sharma S. Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life. Cancers (Basel). 2019;11. [PMID: 31216701 DOI: 10.3390/cancers11060841] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 9.7] [Reference Citation Analysis]
16 Tournoux-Facon C, Paoletti X, Barbare JC, Bouché O, Rougier P, Dahan L, Lombard-Bohas C, Faroux R, Raoul JL, Bedenne L. Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting. J Hepatol. 2011;54:108-114. [PMID: 21047696 DOI: 10.1016/j.jhep.2010.06.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
17 Lee JW, Yun M, Cho A, Han KH, Kim DY, Lee SM, Lee JD. The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis. Ann Nucl Med. 2015;29:400-408. [PMID: 25652647 DOI: 10.1007/s12149-015-0956-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
18 Dhamoon MS, Moon YP, Paik MC, Boden-Albala B, Rundek T, Sacco RL, Elkind MS. Quality of life declines after first ischemic stroke. The Northern Manhattan Study. Neurology 2010;75:328-34. [PMID: 20574034 DOI: 10.1212/WNL.0b013e3181ea9f03] [Cited by in Crossref: 51] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
19 Shi M, Chen JA, Lin XJ, Guo RP, Yuan YF, Chen MS, Zhang YQ, Li JQ. Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China. World J Gastroenterol 2010; 16(2): 264-269 [PMID: 20066748 DOI: 10.3748/wjg.v16.i2.264] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
20 Leung HW, Liu CF, Chan AL. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma. Radiat Oncol. 2016;11:69. [PMID: 27193904 DOI: 10.1186/s13014-016-0644-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
21 Serper M, Parikh ND, Thiele G, Ovchinsky N, Mehta S, Kuo A, Ho C, Kanwal F, Volk M, Asrani SK, Ghabril MS, Lake JR, Merriman RB, Morgan TR, Tapper EB. Patient-reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology 2022. [PMID: 34990516 DOI: 10.1002/hep.32313] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Meier A, Yopp A, Mok H, Kandunoori P, Tiro J, Singal AG. Role functioning is associated with survival in patients with hepatocellular carcinoma. Qual Life Res 2015;24:1669-75. [PMID: 25502092 DOI: 10.1007/s11136-014-0895-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
23 Mierzynska J, Piccinin C, Pe M, Martinelli F, Gotay C, Coens C, Mauer M, Eggermont A, Groenvold M, Bjordal K, Reijneveld J, Velikova G, Bottomley A. Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review. Lancet Oncol 2019;20:e685-98. [PMID: 31797795 DOI: 10.1016/S1470-2045(19)30656-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 12.5] [Reference Citation Analysis]
24 Diouf M, Bonnetain F, Barbare JC, Bouché O, Dahan L, Paoletti X, Filleron T. Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma. Oncologist 2015;20:62-71. [PMID: 25542450 DOI: 10.1634/theoncologist.2014-0175] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
25 Ryoo BY, Merle P, Kulkarni AS, Cheng AL, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Daniele B, Norquist JM, Chen E, Siegel AB, Zhu AX, Finn RS, Kudo M. Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240. Cancer 2021;127:865-74. [PMID: 33231873 DOI: 10.1002/cncr.33317] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
26 Zou H, Li M, Lei Q, Luo Z, Xue Y, Yao D, Lai Y, Ung COL, Hu H. Economic Burden and Quality of Life of Hepatocellular Carcinoma in Greater China: A Systematic Review. Front Public Health 2022;10:801981. [PMID: 35530735 DOI: 10.3389/fpubh.2022.801981] [Reference Citation Analysis]
27 Shun SC, Chen CH, Sheu JC, Liang JD, Yang JC, Lai YH. Quality of life and its associated factors in patients with hepatocellular carcinoma receiving one course of transarterial chemoembolization treatment: a longitudinal study. Oncologist. 2012;17:732-739. [PMID: 22511265 DOI: 10.1634/theoncologist.2011-0368] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
28 Deng Y, Zhu J, Liu Z, Huang M, Chang DW, Gu J. Elevated systemic inflammatory responses, factors associated with physical and mental quality of life, and prognosis of hepatocellular carcinoma. Aging (Albany NY) 2020;12:4357-70. [PMID: 32145060 DOI: 10.18632/aging.102889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Sternby Eilard M, Hagström H, Mortensen KE, Wilsgaard T, Vagnildhaug OM, Dajani O, Stål P, Rizell M. Quality of life as a prognostic factor for survival in hepatocellular carcinoma. Liver Int 2018;38:885-94. [PMID: 28941130 DOI: 10.1111/liv.13593] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
30 Li L, Yeo W. Value of quality of life analysis in liver cancer: A clinician’s perspective. World J Hepatol 2017; 9(20): 867-883 [PMID: 28804570 DOI: 10.4254/wjh.v9.i20.867] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
31 Muzellec L, Bourien H, Edeline J. Patients' Experience of Systemic Treatment of Hepatocellular Carcinoma: A Review of the Impact on Quality of Life. Cancers (Basel) 2021;14:179. [PMID: 35008343 DOI: 10.3390/cancers14010179] [Reference Citation Analysis]
32 Fan SY, Eiser C, Ho MC. Health-related quality of life in patients with hepatocellular carcinoma: a systematic review. Clin Gastroenterol Hepatol. 2010;8:559-64.e1-10. [PMID: 20304101 DOI: 10.1016/j.cgh.2010.03.008] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 4.8] [Reference Citation Analysis]
33 Woradet S, Songserm N, Promthet S, Parkin DM. Health-Related Quality of Life and Survival of Cholangiocarcinoma Patients in Northeastern Region of Thailand. PLoS One 2016;11:e0163448. [PMID: 27685448 DOI: 10.1371/journal.pone.0163448] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
34 Velanovich V. The association of quality-of-life measures with malignancy and survival in patients with pancreatic pathology. Pancreas 2011;40:1063-9. [PMID: 21785386 DOI: 10.1097/MPA.0b013e31821ad8eb] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
35 Tohme S, Sanin GD, Patel V, Bress K, Ahmed N, Krane A, Tsung A, Steel JL. Health-Related Quality of Life as a Prognostic Factor in Patients After Resection of Hepatic Malignancies. J Surg Res 2020;245:257-64. [PMID: 31421371 DOI: 10.1016/j.jss.2019.07.061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Greten TF, Abou-Alfa GK, Cheng AL, Duffy AG, El-Khoueiry AB, Finn RS, Galle PR, Goyal L, He AR, Kaseb AO, Kelley RK, Lencioni R, Lujambio A, Mabry Hrones D, Pinato DJ, Sangro B, Troisi RI, Wilson Woods A, Yau T, Zhu AX, Melero I. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer 2021;9:e002794. [PMID: 34518290 DOI: 10.1136/jitc-2021-002794] [Reference Citation Analysis]
37 Carr BI, Pujol L. Pain at Presentation and Survival in Hepatocellular Carcinoma. The Journal of Pain 2010;11:988-93. [DOI: 10.1016/j.jpain.2010.01.265] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
38 Bonnetain F. Qualité de vie relative à la santé et critères de jugement en cancérologie. Cancer/Radiothérapie 2010;14:515-8. [DOI: 10.1016/j.canrad.2010.06.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
39 Diouf M, Filleron T, Barbare JC, Fin L, Picard C, Bouché O, Dahan L, Paoletti X, Bonnetain F. The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. J Hepatol. 2013;58:509-521. [PMID: 23178978 DOI: 10.1016/j.jhep.2012.11.019] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 3.9] [Reference Citation Analysis]
40 Gandhi S, Khubchandani S, Iyer R. Quality of life and hepatocellular carcinoma. J Gastrointest Oncol. 2014;5:296-317. [PMID: 25083303 DOI: 10.3978/j.issn.2078-6891.2014.046] [Cited by in F6Publishing: 26] [Reference Citation Analysis]
41 Li L, Mo F, Hui EP, Chan SL, Koh J, Tang NLS, Yu SCH, Yeo W. The association of liver function and quality of life of patients with liver cancer. BMC Gastroenterol 2019;19:66. [PMID: 31046687 DOI: 10.1186/s12876-019-0984-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
42 Terrin N, Rodday AM, Parsons SK. Joint models for predicting transplant-related mortality from quality of life data. Qual Life Res 2015;24:31-9. [PMID: 24129669 DOI: 10.1007/s11136-013-0550-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
43 Kensinger CD, Feurer ID, O'Dell HW, LaNeve DC, Simmons L, Pinson CW, Moore DE. Patient-reported outcomes in liver transplant recipients with hepatocellular carcinoma. Clin Transplant 2016;30:1036-45. [PMID: 27291713 DOI: 10.1111/ctr.12785] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
44 Crehange G, Bonnetain F, Peignaux K, Truc G, Blanchard N, Rat P, Chauffert B, Ghiringhelli F, Maingon P. Preoperative radiochemotherapy for resectable localised oesophageal cancer: a controversial strategy. Crit Rev Oncol Hematol. 2010;75:235-242. [PMID: 20044267 DOI: 10.1016/j.critrevonc.2009.11.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
45 Li L, Chan SL, Mo F, Hui EP, Koh J, Chan AKC, Tang NLS, Lee KF, Lai PBS, Yu SCH, Yeo W. Correlations of health-related quality of life with serum inflammatory indicators IL-8 and mIBI in patients with hepatocellular carcinoma. Cancer Manag Res 2019;11:2719-27. [PMID: 31040713 DOI: 10.2147/CMAR.S178482] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
46 Moser M, Radu IP, Dufour JF. Effects of Home Care on patients with hepatocellular carcinoma treated with sorafenib. JGH Open 2021;5:864-70. [PMID: 34386593 DOI: 10.1002/jgh3.12533] [Reference Citation Analysis]